Drug Profile


Alternative Names: Anti CTLA 4 monoclonal antibody Pfizer; CP-675; CP-675206; Ticilimumab

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Developer Amgen; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Fondazione IRCCS Istituto Nazionale dei Tumori; Grupo Espanol de Tumores Neuroendocrinos; Immunocore; Institute Gustave-Roussy; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Health and Medical Research Council; Northwestern University; Pfizer; Seoul National University Hospital; University of Maryland Greenbaum Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
  • Phase II Breast cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Germ cell and embryonal neoplasms; Glioblastoma; Hepatocellular carcinoma; Lung cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma
  • Phase I/II Malignant melanoma; Oesophageal cancer
  • Phase I Colorectal cancer; Diffuse large B cell lymphoma; Renal cell carcinoma; Thyroid cancer; Urogenital cancer
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 16 Aug 2017 ARCAGY/GINECO-Group and AstraZeneca plans a phase I/II trial for Ovarian cancer, Fallopian tube cancer, and primary Peritoneal adenocarcinoma(Combination therapy, First-line therapy, Neoadjuvant therapy) in France in September 2017 (NCT03249142)
  • 10 Aug 2017 Sidney Kimmel Comprehensive Cancer Center plans a phase II trial for Non-small cell lung cancer (Neoadjuvant therapy, Late-stage disease) (NCT03237377)
  • 03 Aug 2017 University Medical Center Groningen and AstraZeneca plan a phase I trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in Netherlands (NTR6553)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top